ICON holds lead as most active CRO, GlobalData finds
Irish contract research organization ICON (Nasdaq: ICON) has retained its position as the most active CRO worldwide in the first quarter of 2025, according to a new analysis by GlobalData.
The report highlights that Russia continued to initiate the highest number of clinical trials in Europe, despite the ongoing conflict with Ukraine. France climbed from fourth to second place in the region, reflecting a notable shift in European clinical trial activity.
The report provides a detailed snapshot of the global clinical research landscape. The findings show that large- and mega-cap sponsors, led by AstraZeneca (LSE: AZN), drove much of the trial activity, particularly in oncology and central nervous system (CNS) diseases.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze